| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.0 | 0.8 |
| Net income | -15.5 | -17.5 |
| EPS (diluted, $ a share) | $-0.06 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +36.5% |
|---|
10-Q filed with the SEC, NASDAQ: HUMA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Humacyte, Inc.: key numbers
- Share price
- $0.5403Close, Nov 16
- Market cap
- $150M
- Shares outstanding
- 277.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Humacyte, Inc.
All →Humacyte Financial Results
Humacyte reported Q3 2026 financial results, highlighted by a 151% sequential increase in Symvess revenue to $1.0 million. The company remains on track to file a supplemental Biologics License Application (sBLA) for its ATEV in dialysis access with the FDA in November 2026.
- Term
- Q3 2026
“During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second quarter and significantly increasing the number of hospitals ordering Symvess.”
Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte
“Execution of our revamped commercial program for Symvess generated significant momentum during the third quarter. Symvess sales revenue for the third quarter was $1.0 million, more than double our results for the second quarter, and achieved the goal we set for the period.”
Jim Mercadante, Chief Commercial Officer of Humacyte
Humacyte Leadership Change
Humacyte, Inc. appointed life science industry veterans Scott Coward and Paul Kuznik to its Board of Directors, effective September 22, 2026. Coward, a former executive at Exact Sciences, and Kuznik, a former CEO of Bolton Medical, bring extensive experience in commercialization and global operations as the company prepares for the planned launch of its ATEV product in dialysis access.